Tepotinib hydrochloride hydrate

盐酸特泊替尼

Report date: 2023/12/13 14:30:16
NME

Base Information

Drug NameTepotinib hydrochloride hydrate
Drug Alias Name特泊替尼tepotinibtepotinibum特珀替尼Tepmetko +[10] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHepatocyte growth factor receptor inhibitors
TargetsHepatocyte growth factor receptor
Therapy Area/IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms +[4] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryJapan
Original Approved Date2020/03/25
Country/TerritoryCzechiaBelgiumUnited States +[24] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesEmd Serono IncEmd Serono Research & Development Institute IncMerck Europe Bv +[9] 
Inactive CompaniesMerck Healthcare Kgaa, Darmstadt, Germany, An Affiliate Of Merck Kgaa, Darmstadt, GermanyCriterium Inc
Active IndicationsSolid tumoursCarcinoma, Non-Small-Cell LungColorectal Neoplasms
Inactive IndicationsCarcinoma, Hepatocellular

Other Information

ATC CodeL01XE
Related LinksDrugBankKEGG